CELMoDs: Mechanism of action and immunomodulatory activity in MM
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked about the mechanism of action and immunomodulatory activity of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma.
During this interview, Richardson discusses how CELMoDs target the cereblon E3 ubiquitin ligase complex to induce selective protein degradation and immunomodulatory effects. Richardson explains how CELMoDs, such as iberdomide and mezigdomide, differ structurally and functionally from earlier immunomodulatory drugs (IMiDs), resulting in enhanced substrate degradation…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.